Comparing Indobufen and Aspirin with Clopidogrel for Treating Unruptured Brain Aneurysms Using Endovascular Techniques

What this Trial Is About

Researchers are studying the safety and effectiveness of combining two antiplatelet drugs, indobufen and clopidogrel, to prevent blood clot-related events in patients undergoing endovascular treatment for unruptured intracranial aneurysms. This trial compares this combination with the standard treatment of aspirin plus clopidogrel. The goal is to see which regimen better prevents ischemic and bleeding complications after placing stents or flow diverters inside brain vessels. Patients with unruptured intracranial aneurysms scheduled for endovascular procedures will be randomly assigned to one of two groups. The experimental group will take indobufen 100 mg twice daily plus clopidogrel 75 mg once daily, starting five days before the procedure and continuing for 180 days after surgery. The control group will receive aspirin 100 mg once daily plus clopidogrel 75 mg once daily on the same schedule. Treatment continues for six months post-procedure. Participants will be monitored for cerebrovascular thromboembolic events and bleeding events for up to 90 days after surgery. Researchers will also assess platelet function before surgery and track safety through bleeding classifications. The study involves regular follow-ups and evaluations to measure treatment effects on preventing clotting and bleeding complications after the vascular intervention, with the entire participation lasting at least six months.

INdobufen Versus asPirin in Endovascular Unruptured Intracranial Aneurysms Treatment (INPUT)